Literature DB >> 26393289

Brain-blood ratio: implications in brain drug delivery.

Abhijeet D Kulkarni1, Harun M Patel2, Sanjay J Surana3, Veena S Belgamwar4, Chandrakantsing V Pardeshi5.   

Abstract

INTRODUCTION: The brain-blood ratio is an important model correlating the brain-targeting ability of neurotherapeutics with the CNS pharmacokinetics, which need to be presented before the scientific community for exploration of its scientific worth. The purpose of this article is to bring this key concept and its precise discussion to the attention of the researchers. AREAS COVERED: Three major points are discussed herein: First, the significance of brain-blood ratio with respect to investigational neurotherapeutics, and carrier systems and correlation of its research findings with the brain targeting efficiency. Second, the various factors influencing the brain-blood ratio. Third, the various strategies for enhancing the brain-blood ratio. In addition, the benchmark criteria for CNS-likeness of drug molecules and the correlation of brain-blood ratio with brain targeting ability of neurotherapeutics have been tabulated. EXPERT OPINION: The brain-blood ratio (also referred to as the brain-plasma ratio) represents one of the tools available today for estimation of CNS pharmacokinetics. It is preferred over other complicated techniques (in situ brain perfusion and microdialysis) due to its ease of use and practicality. We are optimistic that the brain-blood ratio offers an excellent way of evaluating brain-targeting efficiency of neurotherapeutics effectively. In our opinion, it is a very fundamental aspect of brain bioavailability and needs to be presented in a precise way.

Keywords:  P-glycoprotein; blood–brain barrier; brain pharmacokinetics; brain targeting; brain-blood ratio; brain-plasma ratio; drug delivery

Mesh:

Substances:

Year:  2015        PMID: 26393289     DOI: 10.1517/17425247.2016.1092519

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  6 in total

1.  Synthesis and In Vitro and In Vivo Evaluation of [3H]LRRK2-IN-1 as a Novel Radioligand for LRRK2.

Authors:  Noeen Malik; Andrew N Gifford; Johan Sandell; Daniel Tuchman; Yu-Shin Ding
Journal:  Mol Imaging Biol       Date:  2017-12       Impact factor: 3.488

Review 2.  Drug Design Targeting the Muscarinic Receptors and the Implications in Central Nervous System Disorders.

Authors:  Chad R Johnson; Brian D Kangas; Emily M Jutkiewicz; Jack Bergman; Andrew Coop
Journal:  Biomedicines       Date:  2022-02-07

3.  Microengineered human blood-brain barrier platform for understanding nanoparticle transport mechanisms.

Authors:  Song Ih Ahn; Yoshitaka J Sei; Hyun-Ji Park; Jinhwan Kim; Yujung Ryu; Jeongmoon J Choi; Hak-Joon Sung; Tobey J MacDonald; Allan I Levey; YongTae Kim
Journal:  Nat Commun       Date:  2020-01-10       Impact factor: 14.919

4.  HM30181A, a potent P-glycoprotein inhibitor, potentiates the absorption and in vivo antitumor efficacy of paclitaxel in an orthotopic brain tumor model.

Authors:  Wu Zeng; Betty Yuen Kwan Law; Vincent Kam Wai Wong; Denise So Bik Chan; Simon Wing Fai Mok; Joyce Jia Ying Gao; Rebecca Ka Yan Ho; Xu Liang; Jia Hao Li; Ming Tsung Lee; Weng Li Yoon; Michael P Smolinski; Johnson Yiu Nam Lau; Christopher Wai Kei Lam; Manson Fok
Journal:  Cancer Biol Med       Date:  2020-12-15       Impact factor: 4.248

5.  IVIVC Assessment of Two Mouse Brain Endothelial Cell Models for Drug Screening.

Authors:  Ina Puscas; Florian Bernard-Patrzynski; Martin Jutras; Marc-André Lécuyer; Lyne Bourbonnière; Alexandre Prat; Grégoire Leclair; V Gaëlle Roullin
Journal:  Pharmaceutics       Date:  2019-11-08       Impact factor: 6.321

6.  The emergence of imaging mass spectrometry in drug discovery and development: Making a difference by driving decision making.

Authors:  Stephen Castellino; Nichole M Lareau; Mark Reid Groseclose
Journal:  J Mass Spectrom       Date:  2021-03-16       Impact factor: 1.982

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.